Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study.
about
Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Advantages with prophylactic P ...... , multicenter phase III study.
@en
Advantages with prophylactic P ...... , multicenter phase III study.
@nl
type
label
Advantages with prophylactic P ...... , multicenter phase III study.
@en
Advantages with prophylactic P ...... , multicenter phase III study.
@nl
prefLabel
Advantages with prophylactic P ...... , multicenter phase III study.
@en
Advantages with prophylactic P ...... , multicenter phase III study.
@nl
P2093
P2860
P1476
Advantages with prophylactic P ...... d, multicenter phase III study
@en
P2093
Ai-Mei Jiang
Bai-Hong Zhang
Bi-Yong Ren
Bi-Yun Wang
Fei-Lin Cao
Hong Zheng
Jian Zhang
P2860
P2888
P304
P356
10.1007/S10549-017-4609-6
P407
P50
P577
2017-12-11T00:00:00Z